Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials

Vaccine

Volumn 33, Issue 4, 2015, Pages 577-584

  Leroux Roels, Isabel ^a   Devaster, Jeanne Marie ^b   Leroux Roels, Geert ^a   Verlant, Vincent ^b   Henckaerts, Isabelle ^b   Moris, Philippe ^b   Hermand, Philippe ^b   Van Belle, Pascale ^b   Poolman, Jan T ^b,c   Vandepapelière, Pierre ^b,d   Horsmans, Yves ^e  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GSK   (Belgium)

^c CRUCELL HOLLAND BV   (Netherlands)

^d Neovacs SA   (France)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Adjuvant; Immunosenescence; PhtD; Pneumonia; Streptococcus pneumoniae; Vaccine

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; PLACEBO; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN D VACCINE; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MEMORY CELL; MOUSE; MYALGIA; NONHUMAN; NORMAL HUMAN; PARALLEL DESIGN; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SKIN REDNESS; VACCINATION; ADOLESCENT; ADVERSE DRUG REACTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIAL PROTEINS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; PLACEBOS; PNEUMOCOCCAL VACCINES; SINGLE-BLIND METHOD; STREPTOCOCCUS PNEUMONIAE; T-LYMPHOCYTES; VACCINATION; YOUNG ADULT;

EID: 84920616540     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.052     Document Type: Article

References (44)

1. McElhaney J.E., Effros R.B. Immunosenescence: what does it mean to health outcomes in older adults. Curr Opin Immunol 2009, 21:418-424.
2. Westerink M.A., Schroeder H.W., Nahm M.H. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis 2012, 3:51-67.
3. Liu W.M., van der Zeijst B.A., Boog C.J., Soethout E.C. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum Vac 2011, 7(Suppl):94-98.
4. Williams R.E., Sena A.C., Moorman A.C., Moore Z.S., Sharapov U.M., Drobenuic J., et al. Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak. Vaccine 2012, 30:3147-3150.
5. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755.
6. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:CD000422.
7. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180:48-58.
8. Musher D.M. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults. Clin Infect Dis 2012, 55:265-267.
9. Ridda I., Musher D.M. Is there a potential role for protein-conjugate pneumococcal vaccine in older adults. Australas Med J 2012, 5:231-235.
10. World Health Organization 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Weekly Epidemiological Record 2008, 83:373-384.
11. Clutterbuck E.A., Lazarus R., Yu L.M., Bowman J., Bateman E.A., Diggle L., et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012, 205:1408-1416.
12. Centers for Disease Control and Prevention Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR 2012, 61:394-395.
13. Lipsitch M., Whitney C.G., Zell E., Kaijalainen T., Dagan R., Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. PLoS Med 2005, 2:e15.
14. Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med (Berlin) 2010, 88:135-142.
15. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011, 23:407-413.
16. Malley R., Anderson P.W. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Nat Acad Sci USA 2012, 109:3623-3627.
17. + T cells localising within human upper respiratory-tract mucosal lymphoid tissue. PLoS Pathog 2011, 7:e1002396.
18. H17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011, 9:158-165.
19. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69:949-958.
20. Godfroid F., Hermand P., Verlant V., Denoël P., Poolman J.T. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011, 79:238-245.
21. Khan M.N., Pichichero M.E. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine 2012, 30:2900-2907.
22. Denoël P., Philipp M.T., Doyle L., Martin D., Carletti G., Poolman J.T. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011, 29:5495-5501.
23. Kovaiou R.D., Herndler-Brandstetter D., Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007, 9:1-17.
24. Vandepapelière P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26:1375-1386.
25. Crotty S., Aubert R.D., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004, 286:111-122.
26. Hu X., Ivashkiv L.B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009, 31:539-550.
27. Liao W., Lin J.X., Leonard W.J. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011, 23:598-604.
28. Oliphant C.J., Barlow J.L., McKenzie A.N. Insights into the initiation of type 2 immune responses. Immunology 2011, 134:378-385.
29. Profita M., Chiappara G., Mirabella F., Di Giorgi R., Chimenti L., Costanzo G., et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003, 58:573-579.
30. Ma D.Y., Clark E.A. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009, 21:265-272.
31. Cerutti A., Puga I., Cols M. Innate control of B cell responses. Trends Immunol 2011, 32:202-211.
32. + T cells with diverse cytokine profiles. Nat Med 2005, 11:1113-1117.
33. + T cells specific for defined antigens according to CD154 expression. Nat Med 2005, 11:1118-1124.
34. Shi Y., Liu C.H., Roberts A.I., Das J., Xu G., Ren G., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006, 16:126-133.
35. Maecker H.T., Maino V.C., Picker L.J. Immunofluorescence analysis of T-cell responses in health and disease. J Clin Immunol 2000, 20:391-399.
36. A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011, 31:443-454.
37. + T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 2010, 28:7016-7024.
38. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10:471-486.
39. Shi Y., Yamazaki T., Okubo Y., Uehara Y., Sugane K., Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 2005, 175:3262-3267.
40. Wu Y.C., Kipling D., Dunn-Walters D.K. Age-related changes in human peripheral blood IGH repertoire following vaccination. Front Immunol 2012, 3:193.
41. Haynes L., Swain S.L. Why aging T cells fail: implications for vaccination. Immunity 2006, 24:663-666.
42. Kadioglu A., Coward W., Colston M.J., Hewitt C.R., Andrew P.W. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004, 72:2689-2697.
43. van Hoek A.J., Andrews N., Waight P.A., George R., Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 2012, 7:e39150.
44. Brookes R., Ming M., Williams K., Hopfer R., Gurunathan S., Bologa M., et al. Vaccination of humans with pneumococcal histidine triad D (PhtD) elicits functional antibodies. Proceedings of the eighth international symposium on pneumococci and pneumococcal diseases (ISPPD-8) 2012, 581. Poster 269.